Health

Gonadorelin, a decapeptide identical in sequence to gonadotropin-releasing hormone, is believed to occupy a foundational position in endocrine signaling research. Since its structural elucidation in the twentieth century, the peptide has served as a conceptual bridge between neurochemical signaling and systemic hormonal coordination within the research model.

Contemporary scientific discourse increasingly frames Gonadorelin not merely as a reproductive regulator, but as a finely tuned molecular signal whose rhythmic release, receptor interactions, and downstream cascades offer insight into broader principles of cellular communication, feedback regulation, and temporal encoding. This article explores Gonadorelin through a research-oriented lens, supporting  its molecular characteristics, signaling properties, hypothesized systemic roles, and emerging investigative domains. The discussion relies on established scientific knowledge while maintaining speculative language appropriate to ongoing inquiry.

Molecular Identity and Structural Considerations

Gonadorelin is a linear decapeptide composed of ten amino acids arranged in a highly conserved sequence across vertebrate species. This conservation has long intrigued researchers, as it suggests evolutionary pressure to preserve both structure and function. From a biochemical perspective, the peptide’s relatively small size belies its extensive signaling reach within the research model.

At the molecular level, Gonadorelin may be viewed as an archetypal neuropeptide, synthesized as part of a larger precursor molecule and subsequently processed into its active form. Its tertiary simplicity allows it to interact with a specific G protein-coupled receptor, commonly referred to as the gonadotropin-releasing hormone receptor. Research indicates that subtle alterations in amino acid composition or terminal modifications may significantly alter receptor affinity, signaling bias, and degradation kinetics. These observations have fueled interest in Gonadorelin analogs as experimental tools for probing receptor dynamics and intracellular signaling selectivity.

Receptor Interaction and Intracellular Signaling Cascades

The interaction between Gonadorelin and its receptor represents a classic model for ligand-receptor specificity in mammalian endocrine research. Upon binding, the receptor undergoes conformational changes that may activate multiple intracellular pathways, including phospholipase C signaling, calcium mobilization, and protein kinase activation. Rather than functioning as a simple on-off switch, Gonadorelin signaling appears to encode information through frequency and amplitude modulation.

Research suggests that pulsatile exposure to Gonadorelin might generate distinct intracellular responses compared to continuous exposure, even when total peptide availability remains constant. This phenomenon has positioned Gonadorelin as a central example in studies of temporal signaling, where timing itself becomes a biologically meaningful variable. Investigations purport that this temporal encoding may influence gene transcription patterns, receptor recycling, and cellular sensitivity over time.

Temporal Dynamics and Rhythmic Signaling

One of the most compelling research properties of Gonadorelin lies in its rhythmic release pattern. Unlike many signaling molecules that operate through steady concentrations, Gonadorelin appears to function optimally through discrete pulses. Scientific inquiry has long theorized that this pulsatility allows the mammalian model to maintain responsiveness while avoiding receptor desensitization.

From a systems biology perspective, Gonadorelin may serve as a model for understanding how oscillatory signals regulate complex physiological networks. Computational analyses and laboratory-based research models have explored how variations in pulse frequency, duration, and interval might translate into differential downstream signaling outcomes. These explorations extend beyond reproductive endocrinology, offering conceptual frameworks potentially relevant to circadian biology, metabolic regulation, and adaptive feedback systems as they prove relevant to mammalian models.

Genetic Regulation and Transcriptional Influence Research

Beyond immediate signaling cascades, Gonadorelin is thought to potentially exert a longer-term interaction with or modulation of gene expression. Research indicates that activation of its receptor may alter transcriptional programs associated with cellular differentiation, hormone synthesis, and receptor expression itself. This layered regulatory architecture suggests that Gonadorelin signaling may participate in both rapid and delayed regulatory loops within the research model.

Epigenetic considerations have also entered the conversation. Some investigations hypothesize that repeated Gonadorelin signaling might influence chromatin accessibility or transcription factor recruitment in target cells. While these concepts remain under active exploration, they underscore the peptide’s potential relevance to developmental biology and long-term cellular adaptation.

Possible Role in Neuroendocrine Integration Research

Gonadorelin seems to occupy a unique intersection between neural signaling and endocrine output. Synthesized within specialized neurons, the peptide appears to translate neural inputs into hormonal coordination. This positioning has encouraged researchers to use Gonadorelin as a proxy for studying neuroendocrine integration more broadly.

Research models have examined how external stimuli such as environmental cues, stress signals, and metabolic states might modulate Gonadorelin synthesis and release. These lines of inquiry suggest that the peptide may function as an integrative node, aligning internal physiological states with external conditions. Such hypotheses elevate Gonadorelin from a single-pathway regulator to a dynamic mediator of cell-wide coherence.

Investigative Implications in Endocrine Research Models

Within laboratory settings, Gonadorelin has been widely referenced as a molecule suited for evaluationg receptor responsiveness, signaling fidelity, and feedback regulation. Its well-characterized sequence and receptor interaction profile make it an ideal benchmark for experimental design. Researchers often employ Gonadorelin to calibrate assays measuring gonadotropin synthesis, second messenger generation, or transcriptional responses.

Beyond traditional endocrine studies, Gonadorelin has found relevance in comparative signaling research. By examining how different cell types respond to identical Gonadorelin stimuli, investigators gain insight into cell-specific signaling architectures and receptor coupling strategies. These approaches may inform broader theories of cellular specialization within multicellular models.

Emerging Hypotheses Beyond Reproductive Signaling

While historically associated with reproductive axis regulation, Gonadorelin has increasingly been discussed in the context of broader biological roles. Some research indicates that its receptor may be expressed in tissues not classically associated with gonadotropin regulation. This observation has led to hypotheses that Gonadorelin signaling might support processes such as cellular proliferation, differentiation, or metabolic coordination in context-dependent ways.

In systems-level analyses, Gonadorelin has been theorized to contribute to network stability by participating in feedback loops that extend beyond a single hormonal axis. These speculative models propose that the peptide’s rhythmic signaling might synchronize multiple physiological subsystems, thereby supporting cellular homeostasis under changing conditions.

Conclusion

Gonadorelin remains one of the most intellectually rich peptides in contemporary biological research. Far from being limited to a narrow endocrine function, the peptide embodies key principles of molecular signaling, temporal regulation, and systems integration within the mammalian model. Its conserved structure, rhythmic signaling properties, and multifaceted intracellular impacts continue to inspire investigation across disciplines ranging from neuroendocrinology to computational biology. Researchers interested in further studying this compound are encouraged to visit Core Peptides.

References

[i] Stamatiades, G. A., & Kaiser, U. B. (2017). Gonadotropin regulation by pulsatile GnRH: Signaling and transcriptional control.Endocrinology, 158(11), 3369–3380.
 https://doi.org/10.1210/en.2017-00425

[ii] Navarro, V. M., & Tena-Sempere, M. (2012). New insights into the control of pulsatile GnRH release.Frontiers in Endocrinology, 3, 48. https://doi.org/10.3389/fendo.2012.00048

[iii] Whitlock, K. E., & Schlarb, J. E. (2019). Is gonadotropin-releasing hormone neurons dispensable for reproductive neuroendocrine function?Journal of Neuroendocrinology, 31(1), e12696. https://doi.org/10.1111/jne.12696

[iv] Flanagan, C. A., & Manilall, J. D. (2017). Gonadotropin-releasing hormone receptors: Structure, ligand binding and intracellular signaling.Frontiers in Endocrinology, 8, 274. https://doi.org/10.3389/fendo.2017.00274

[v] Ohlsson, B. (2016). Gonadotropin-Releasing Hormone and its physiological and pathophysiological roles in relation to the structure and function of the gastrointestinal tract.European Surgical Research, 57(1-2), 22–33. https://doi.org/10.1159/000445717

April 18 (UPI) — President Donald Trump signed an executive order Saturday to accelerate research for some psychedelic drugs to treat mental health disorders.

Surrounded by podcaster Joe Rogan and veterans, the president signed the order that could lead to use of the psychedelics in controlled, therapeutic settings.

“We’re taking this decision, this decisive step, to confront one of the most urgent public health challenges facing our nation, the mental health crisis,” Trump said Saturday in the Oval Office.

“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump said.

The order directs the Food and Drug Administration to speed its review of new treatments. Trump said the order applies to certain drugs that are already in the “advanced stages of clinical trials.”

Rogan said he sent the president “some information” about the drugs after he heard about them on his podcast, The Hill reported.

“I sent him that information. The text message that came back: ‘Sounds great. Do you want FDA approval? Let’s do it.’ Literally that quick,” Rogan said.

Trump mentioned ibogaine, which has been used to treat post-traumatic stress disorder in other countries. He said the administration would be “opening the pathway” for the drug to be included in the Right to Try Act, which allows terminally ill patients to participate in clinical trials for treatments still under FDA review, The Hill reported. Trump signed that act into law in 2018.

“Under this new program in this administration, drugs can get approved in weeks, not a year or year plus, but in weeks, if they are in line with our national priorities,” FDA Commissioner Martin Makary said at the signing.

“This is an unmet public health need, and there are potentially promising treatments,” Makary said. “That’s why there’s a sense of urgency around this. That’s why we’re doing it now.”

In 2024, 471 U.S. service members died by suicide, and there were 1,515 attempts reported, according to the Pentagon’s Annual Report on Suicide in the Military.

Some of the drugs included are ibogaine; LSD; psilocybin; known as magic mushrooms; and MDMA, known as ecstasy. Trump added that the government had just committed $50 million in additional funding for ibogaine research, The Post reported.

“Federal prohibition of psychedelic medicine in America is over,” said W. Bryan Hubbard, an advocate for access to ibogaine, The Washington Post reported.

Kevin Sabet, who was a White House drug policy adviser over three presidential administrations, disagreed. He said the order will “send the wrong message” and encourages hasty, potentially dangerous research.

“People need to realize there is little to no evidence for most of these drugs and most of the conditions they claim to alleviate,” Sabet, president of Smart Approaches to Marijuana, wrote in a text message to The Post.

Health and Human Services Secretary Robert F. Kennedy Jr. has championed the idea of using psychedelics to help with mental health conditions. On Saturday, he said officials owed it to veterans “to turn over every stone.”

“It’s disturbing to me and to the president that hundreds, in fact, thousands of veterans are having to travel to Mexico or other countries to experiment with interventions that hold great promise,” Kennedy said.

SACRAMENTO — — After nearly a year of often tortuous negotiations, Gov. Arnold Schwarzenegger and Assembly Speaker Fabian Nunez have settled on a plan to extend health insurance to 3.6 million Californians who lack it through a new tax on all employers and tobacco sales, officials said Friday.

The leaders have agreed to ask voters in November to require employers to spend between 1% and 6.5% of their payroll costs on healthcare. The measure would also levy a tax on tobacco sales of at least $1.50 a pack, although it could be as high as $2 a pack, the aides said.

“It’s an incredible plan,” Nunez (D-Los Angeles) said in an interview. “I couldn’t tell you there is one single outstanding issue that is a make-or-break issue.”

Daniel Zingale, a senior advisor to Schwarzenegger, said the leaders “have agreed on the framework of the healthcare reform that will go before voters.”

Nunez’s office on Friday filed a companion bill that contains the details of how the plan would work and scheduled an afternoon vote in the Assembly on Monday, presuming a few details will be resolved over the weekend.

That bill does not contain the taxes or other measures that would provide the $14 billion a year needed to finance the ambitious overhaul and would not take effect unless the ballot measure passes. That puts Democratic lawmakers in the highly unusual position of voting on the plan without being able to assess whether the intricate financing scheme will be adequate. Republicans have already vowed to vote against the measure.

The moves came as Schwarzenegger promised to call an emergency session of the Legislature for early January to make cuts to the state’s budget. The governor’s office estimates the projected gap may reach as high as $14 billion by July 2009, which is threatening to sap political momentum from the healthcare plan.

On Thursday, Senate President Pro Tem Don Perata (D-Oakland) said that while he supported most of the Nunez-Schwarzenegger plan, he intends to delay a Senate vote on the measure until the governor outlines how his proposed budget cuts will affect existing healthcare programs for the poor and disabled

The Nunez-Schwarzenegger plan would require almost all Californians to obtain private medical insurance. Those earning below 2 1/2 times the poverty level — or $51,625 for a family of four — would receive state subsidies to pay for most of their premiums.

Families earning more than that but no more than four times the poverty level — $82,600 for a family of four — would be able to fully deduct any premium costs that exceed 5.5% of their incomes, which translates to $4,543 for a family at the top of that range. There would also be tax credits for people who retire before they qualify for Medicare at age 65 so that they would not spend more than 10% of their savings on insurance.

Under the plan, California employers with payrolls of up to $250,000 a year would have to spend at least 1% on healthcare for their workers. Those that didn’t would pay into a state-run health insurance pool that would help secure coverage for the employees. Companies with payrolls up to $1 million would have to pay 4% and those with payrolls up to $15 million would have to pay 6%. All larger companies would pay 6.5%.

The plan would extend coverage to 800,000 low-income children and many impoverished adults who currently do not qualify for public programs. It would omit about 1 million illegal immigrants as well as another 500,000 people who are poor but either refuse public coverage or cannot document that they are legal residents.

The bill the Assembly will consider Monday would upend the way California’s insurance market works. Insurers would be barred from denying coverage to people because of existing medical ailments and would have to spend at least 85% of premiums on medical care.

Many insurers, including Kaiser Permanente and Blue Shield of California, have supported this approach for months, but the state’s largest insurer, Blue Cross of California, is preparing to fight the ballot measure.

The plan also contains a $2.3-billion tax on hospitals, supported by the industry, that would pay for increased MediCal payments to doctors and institutions that treat the poor. That tax would also qualify California to draw another $2.3 billion from the federal government.

Those involved in the negotiations said the only major piece still to be ironed out is the tax on tobacco. Schwarzenegger and Nunez have been negotiating with the tobacco companies to see if they can craft the provision in a way that will win their acquiescence, if not their support. But aides said they are also still discussing whether $1.50 a pack will be enough to fund the plan, or whether they will need $2 a pack — an amount tobacco industry leaders say they will oppose.

We “don’t think funding expanding programs with a declining revenue source makes sense,” said David Sutton, a spokesman for Philip Morris USA in Richmond, Va.

Perata also expressed major reservations about the tobacco tax, and said that provisions being insisted upon by the tobacco industry, including immunity from civil and criminal lawsuits, would doom the deal.

The California Nurses Assn., which has favored replacing private insurers with a state-run provider of medical coverage, said the bill was being pushed through the Legislature. “Just as with the energy deregulation fiasco, legislators are being rushed into voting in the dark on a sweeping bill with massive loopholes and serious financial ramifications that no one has adequately reviewed,” said Donna Gerber, the union’s chief lobbyist.

Even some supporters of lawmakers’ efforts were worried that the broader political climate would be insurmountable.

Bob Ross, president of the California Endowment, a Los Angeles-based foundation that favors expanded healthcare, cited as obstacles the state’s weakening economy, the budget gap and the continued standoff between President Bush and the Democratic-led Congress about expanding federal health insurance for children.

“When you do the math on that set of realities, it doesn’t bode well,” Ross said. “So it comes as welcome news that the governor and the speaker are fighting and trying to get something done.”

—

jordan.rau@latimes.com

Times staff writer Nancy Vogel contributed to this report.

The order calls on the federal government to relax restrictions on psychedelics, including ibogaine, for potential treatments.

United States President Donald Trump has signed an executive order to speed up the review of a handful of psychedelic drugs, including the controversial ibogaine.

Trump was joined by podcaster Joe Rogan during Saturday’s Oval Office event.

Rogan, considered one of the most influential podcasters in the country, has been a leading proponent of ibogaine, which is derived from a plant that grows in West Africa and has been embraced by some military veteran groups as a treatment for post-traumatic stress.

Speaking at the event, Rogan recounted how he had previously texted information to Trump about ibogaine.

He recalled that the president quickly texted back: “Sounds great. Do you want FDA [Food and Drug Administration] approval? Let’s do it.”

Advocacy groups have long pushed for more research into the possible use of psychedelics to treat an array of issues, including depression.

“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump said at the signing.

“If these turn out to be as good as people are saying, it’s going to have a tremendous impact.”

At one point, the president quipped that he would be open to taking psychedelics himself: “Can I have some, please? I’ll take some.”

But he quickly pivoted away from the joke. “I don’t have time to be depressed. You know, if you stay busy enough, maybe that works, too. That’s what I do,” he said.

Increasing research into psychedelics has proven a rare issue with bipartisan support in the US, where ibogaine and other psychedelics remain banned under the federal government’s most restrictive category for illegal drugs.

Health Secretary Robert F Kennedy Jr had previously pledged to ease access to psychedelics for medical use.

Trump’s executive order calls on the Department of Health and Human Services to direct at least $50m to states that have enacted or are developing programmes to advance psychedelic drugs for serious mental illness.

It also arrives ahead of several actions from the FDA to loosen restrictions.

This week, the agency will issue so-called “national priority” vouchers for three psychedelics, which the agency’s commissioner, Marty Makary, said will allow certain drugs to be approved quickly “if they are in line with our national priorities”.

The FDA is also taking steps to clear the way for the first-ever human trials of ibogaine in the US. Previous research had been stalled by concerns over the drug potentially triggering fatal heart problems.

Ibogaine was first used by members of the Bwiti religion in African nations like Gabon for religious ceremonies.

Rogan’s endorsement helped boost Trump ahead of the 2024 presidential election. He has since publicly questioned the administration’s war with Iran, saying it runs counter to Trump’s campaign pledges.

Also present on Saturday was Marcus Luttrell, a former Navy SEAL whose memoir about his time in Afghanistan, Lone Survivor, was later made into a film.

He praised ibogaine during the ceremony: “It absolutely changed my life for the better.”

Adam Thomas has been battling a health condition, brought on by an autoimmune disease, which means he struggles to walk and was enduring ‘pretty unbearable’ pain

Adam Thomas has been battling a health condition, brought on by an autoimmune disease, for years. During a conversation on I’m A Celebrity tonight, boxer David Haye will be seen trying to get Adam to take taking part in the Termite Terror, unable to accept that the former soap actor just isn’t feeling up to it.

Trying to sleep, Adam admits it would be hard to get through it today because he is feeling dehydrated, but David is seen raging: “Dehydrated?! We’ve all got the same amount of water! Adam is doing it and that’s it!”

David’s co-stars continually try to remind him that their campmate isn’t feeling well enough to get through it, but he becomes hellbent on trying to force Adam into it. He continues: “When is your top form gonna come? Why aren’t we forcing this dude to go and do it? Coincidentally, every time there’s something to do, he’s not feeling well!”

It is at that point that Scarlett, clearly in despair at the situation developing, says: “Stop it David, he’s not well!” Adam previously said he had been in pain every day since his diagnosis – but he had finally found something that would help.

“I’ve been struggling with this autoimmune disease now for about two and a half years. It’s been tough. I’m not overexaggerating when I say this but literally within two and a half years, every day I’ve been in pain,” he explained.

“It’s difficult but now I feel like I’ve found – because I’ve been on so many different meds and trying so many different things, back and forth from doctor’s and hospitals.” Back in 2024, Adam explained that he could “barely walk” and was enduring “pretty unbearable” pain due to his arthritis. Adam took to Instagram and told his followers: “The pain is pretty unbearable at the moment, it’s as if my whole body is seizing up!! The pain was bad before, but it’s a lot worse now… how why???

“Now I wish I never came off the methotrexate because I would take that pain to this every day of the week! I’ve just started my new medication today which takes 12 weeks to take effect and even then it might not work so am not too sure what I can do to ease the pain until then?? I’ve had my steroid injections and it literally lasted a week …

“Going to check in at the hospital tomorrow to see what pain relief I can get, because I can’t carry on like this!” Arthritis is a common ailment causing pain and inflammation in the joints, according to the NHS. Main treatments include lifestyle changes, physiotherapy, medication, and in severe cases, surgery. However, there’s no known cure.

An orthopaedic surgeon said that arthritis can be “very debilitating” and may appear in unexpected areas. He explained that while people often think of hips and knees being affected, they don’t usually consider the hands.

Talking about the pain which is often overlooked, Dr Tom Naylor said that “when you’ve got arthritis pain in the thumb right there (video below) it affects so much of what you do on a daily basis. And it really is debilitating for people who have this”.

Speaking on BBC Morning Live, he explained arthritis as a term that causes pain, stiffness and inflammation in the joints. He said: “It literally means inflammation of a joint.”

Talking about CMCJ, which stands for Carpometacarpal joint, he said that it was all to do with the “joint down at the bottom of the thumb and what happens is the joint starts to wear away and the cartilage starts to get more and more worn.

“Even a deformity can start to form and it impacts everything that you do with your hands.” Speaking about treatments for this type of arthritis, the doctor said: “With all types of arthritis, we tend to follow was called a stepwise approach to treatment.”

Like this s tory? F or more of the latest showbiz news and gossip, follow Mirror Celebs on TikTok , Snapchat , Instagram , Twitter , Facebook , YouTube and Threads .

Health Secretary Robert F. Kennedy Jr. on Thursday faced federal lawmakers for the first time since September as he sought to defend a more than 12% proposed cut to his department’s budget and dodge arrows from angry Democrats along the way.

In his testimony before the House Ways and Means Committee, kicking off an expected sprint of seven budget hearings he’ll attend across congressional committees and subcommittees over the next week, Kennedy emphasized the administration’s work to reform dietary guidelines and crack down on waste, fraud and abuse.

Republicans on the committee praised Kennedy as a “breath of fresh air” and asked him to promote his department’s recent actions. Democrats, who have been furious over Kennedy’s sweeping overhaul of the U.S. Department of Health and Human Services, largely had a different agenda.

They needled Kennedy on what they viewed as the Trump administration’s hypocrisy on fraud, demanded to know why he was cutting budgets for various programs and slammed his efforts to pull back vaccine recommendations and messaging, which they said have caused unnecessary deaths.

Kennedy fired back, often raising his voice as he accused the Democrats of misrepresenting his work and past statements.

Here are three standout moments from Thursday’s hearing:

A standoff over measles

One heated exchange early in the hearing came between Kennedy and Rep. Linda Sanchez. The California Democrat decried recent measles outbreaks across the U.S. and asked Kennedy to answer for the fact that under his leadership, the Centers for Disease Control and Prevention pulled back public health messaging supporting vaccination.

“As a mother, this horrifies me,” Sanchez said. “Did President Trump approve your decision to end CDC’s pro-vaccine public messaging campaign?”

Kennedy repeatedly refused to answer, saying first he wanted to respond to the “misstatements that you’ve made” and later praising the Trump administration’s record on preventing measles, although protections against the disease have eroded in some parts of the country as vaccination rates have dropped.

“That’s not answering my question,” Sanchez said as the two talked over each other.

But Sanchez also got Kennedy, a longtime anti-vaccine activist before he entered politics, to acknowledge that a 6-year-old who died of measles last year in West Texas could have potentially been saved with vaccination.

“Do you agree with the majority of doctors that the measles vaccine could have saved that child’s life in Texas?” she asked.

“It’s possible, certainly,” Kennedy said.

RFK Jr. denies talking about Black children being ‘re-parented’

A fight erupted between Kennedy and Rep. Terri Sewell, a Democrat from Alabama, when Kennedy vehemently denied making remarks he’d said in 2024.

The comments dated back to when Kennedy was a presidential candidate. On the “High Level Conversations” podcast last July, he said, “Psychiatric drugs — which every Black kid is now just standard put on Adderall, SSRIs, benzos, which are known to induce violence, and those kids are going to have a chance to go somewhere and get re-parented to live in a community where there’ll be no cellphones, no screens, you’ll actually have to talk to people.”

“Have you ever re-parented, or parented, I should say, a Black child?” Sewell asked, as her staff held up a poster featuring an abbreviated version of the quote.

“I don’t even know what that phrase means,” Kennedy said. “I’m not going to answer something I didn’t say.”

“You’re making stuff up,” he later claimed.

A recording of the podcast shows he made the comments during a conversation about free rehabilitation facilities he was proposing opening at the time in rural areas around the country.

Health and Human Services spokesperson Emily Hilliard said Kennedy before joining the administration was referring to spaces where young people facing alienation, mental health challenges and despair could get re-parented, which she said was a psychotherapy term for “developing the emotional regulation, discipline, boundaries, and self-worth that may not have been established in childhood.”

For Kennedy and his former party, civility is the exception

Kennedy spent most of his life as a Democrat, the scion of one of the nation’s most famous political families. Both Republicans and Democrats during the hearing began their remarks by expressing their admiration of Kennedy’s relatives, among them former President John F. Kennedy.

But again and again throughout Thursday’s hearing, the fraying of bonds between Kennedy and his former party was on full display as spiteful comments were passed back and forth.

The Health secretary grew defensive and visibly agitated. He repeatedly criticized Democratic lawmakers for not giving him a word in edgewise.

“They’ve all shut me up,” Kennedy said at one point. “They give a little speech that they can go and market, you know, for fundraising, and they don’t allow me to answer the question.”

On a few rare occasions, the exchanges were civil. One representative, Gwen Moore of Wisconsin, used humor to make that happen.

“I promise to give you easy, comfortable questions if you don’t yell at me and hurt my feelings,” she told Kennedy. He promised he wouldn’t.

Swenson writes for the Associated Press.